Clinical Trial Update: PCV24 Clinical Trial in Infants and Young Children Aged 2 Months (Minimum 6 Weeks) to 71 Months [Phase 2]

View source ↗

Summary

Ongoing Phase 2 clinical trial evaluating the safety and immunogenicity of the PCV24 pneumococcal conjugate vaccine in infants and young children aged 2 months …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease

Drugs mentioned

• PCV24 (24-valent pneumococcal conjugate vaccine)

Snippet

Sponsor: Shanghai Reinovax Biologics Co.,LTD | Conditions: Pneumococcal Infectious Disease | Phase 2 | Status: RECRUITING